Deciphering the Pathological Mechanisms of Drug-induced Liver Injury: Hepatotoxicity and Liver Damage

Pierce Ren^*
*Correspondence: Pierce Ren, Department of Clinical Sciences, Tianjin University, Tianjin 300072, China, Email:

Introduction

The liver, often referred to as the body's chemical factory, plays a pivotal role in metabolism, detoxification and the synthesis of essential proteins. However, its remarkable capacity to process various substances makes it susceptible to injury, particularly from pharmaceutical drugs. Drug- Induced Liver Injury (DILI) is a serious and potentially fatal condition that poses significant challenges in both clinical practice and drug development. Understanding the intricate pathological mechanisms underlying DILI is crucial for early detection, prevention and effective management. DILI encompasses a spectrum of liver abnormalities, ranging from asymptomatic elevation of liver enzymes to acute liver failure. Clinically, DILI is classified into two main categories: intrinsic and idiosyncratic hepatotoxicity. Intrinsic hepatotoxicity refers to dose-dependent liver injury caused by direct toxicity of a drug or its metabolites, while idiosyncratic hepatotoxicity refers to unpredictable, doseindependent reactions occurring in a small subset of susceptible individuals.

Many drugs undergo biotransformation by hepatic enzymes, leading to the formation of reactive metabolites that can damage hepatocytes. The cytochrome P450 system, particularly CYP3A4, plays a crucial role in drug metabolism. Reactive Oxygen Species (ROS) generated during drug metabolism can overwhelm the liver's antioxidant defense mechanisms, leading to oxidative stress and subsequent hepatocellular injury. Some drugs disrupt mitochondrial function, impairing ATP production and triggering apoptosis or necrosis of hepatocytes. In susceptible individuals, certain drugs can elicit an immune response characterized by the activation of T cells and the release of pro-inflammatory cytokines, leading to hepatocyte damage. Drug-induced autoimmune hepatitis can occur due to molecular mimicry or direct activation of autoreactive T cells by drug metabolites, resulting in chronic liver inflammation. Drugs can interfere with bile secretion or bile flow through various mechanisms, such as inhibition of hepatic transporter proteins or direct damage to bile duct epithelial cells, leading to cholestasis and hepatocellular injury [1].

Description

Some drugs can induce hepatic steatosis by altering lipid metabolism, promoting triglyceride accumulation within hepatocytes and impairing liver function. Certain medications, such as corticosteroids and antipsychotics, can disrupt glucose metabolism, leading to insulin resistance and non-alcoholic fatty liver disease (NAFLD). Early detection and diagnosis of DILI rely on clinical suspicion, thorough medication history and monitoring of liver function tests. Liver biopsy may be necessary to confirm the diagnosis and assess the extent of liver damage. Management involves discontinuation of the offending drug, supportive care, and, in severe cases, liver transplantation. Additionally, efforts are underway to develop biomarkers and predictive models to identify individuals at risk of DILI and improve drug safety during the preclinical and clinical stages of drug development [2].

Drug-induced liver injury represents a complex interplay of genetic, environmental and pharmacological factors, leading to hepatocellular damage through various pathological mechanisms. Understanding these mechanisms is essential for elucidating the underlying pathophysiology, improving diagnostic accuracy and developing targeted therapeutic strategies to mitigate the risk of DILI. By integrating multidisciplinary approaches, including pharmacogenomics, immunology and toxicology, researchers aim to advance our knowledge of DILI and enhance drug safety profiles, ultimately improving patient outcomes and public health [3].

Genetic factors play a significant role in the predisposition to DILI. Variations in genes encoding drug-metabolizing enzymes, transporters and immunerelated proteins can influence an individual's susceptibility to hepatotoxicity. For example, polymorphisms in genes encoding Human Leukocyte Antigen (HLA) molecules have been linked to an increased risk of idiosyncratic DILI for certain drugs like flucloxacillin and amoxicillin-clavulanate. Several factors can increase the risk of developing DILI, including pre-existing liver disease, age, concomitant use of hepatotoxic medications and alcohol consumption. Patients with underlying liver conditions, such as viral hepatitis or NAFLD, are particularly vulnerable to DILI due to compromised liver function and reduced capacity for drug metabolism and detoxification. While pharmaceutical drugs are a common cause of DILI, herbal and dietary supplements have also been implicated in liver injury. The lack of regulation, inconsistent quality control and potential interactions with prescription medications make herbal supplements a significant concern for hepatotoxicity. Certain herbs, such as kava, green tea extract and black cohosh, have been associated with hepatotoxic reactions [4].

Advancements in omics technologies, such as genomics, transcriptomics, proteomics and metabolomics, hold promise for identifying novel biomarkers and molecular pathways involved in DILI pathogenesis. Integrating these omics data with clinical phenotypes and environmental factors can facilitate personalized risk assessment and predictive modeling for DILI. Furthermore, the development of in vitro models, organ-on-a-chip platforms and computational simulations offers innovative approaches to predict drug-induced liver toxicity and screen potential drug candidates more efficiently. Drug-induced liver injury is a multifaceted phenomenon with complex underlying mechanisms involving drug metabolism, immune responses and genetic predisposition. Continued research efforts are essential to improve our understanding of DILI pathophysiology, enhance diagnostic capabilities and develop preventive strategies to minimize the risk of liver damage associated with pharmaceutical drugs and other hepatotoxic agents [5].

Conclusion

Herbal remedies and traditional medicines derived from plants, animals, or minerals are commonly used worldwide for various health conditions. While perceived as natural and safe, some herbal products contain potent hepatotoxic compounds that can cause liver injury. Regulatory agencies and healthcare providers should raise awareness about the potential risks associated with herbal and traditional medicines, promote evidence-based practices and encourage patients to disclose their use of such products to avoid adverse outcomes. DILI poses significant public health challenges, including increased healthcare costs, patient morbidity and mortality and regulatory burdens on pharmaceutical companies. Surveillance systems, collaborative research initiatives and educational campaigns are essential for monitoring DILI trends, improving drug safety practices and enhancing public awareness of the risks associated with medication use.

Drug-induced liver injury is a complex and multifactorial condition influenced by genetic, environmental and pharmacological factors. Continued efforts to elucidate the underlying mechanisms, improve diagnostic methods and implement preventive measures are crucial for minimizing the incidence and impact of DILI on individual patients and public health systems worldwide.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Liang, Dan, Yanping Guan, Jianhong Zhu and Junyan Wu, et al. "Global research trends of Drug-Induced Liver Injury (DILI) in the past two decades: A bibliometric and visualized study." Ann Palliat Med 10 (2021): 8651664-8658664.

Google Scholar, Crossref, Indexed at

2. Lee, William M. "Etiologies of acute liver failure." Thieme Medical Publishers 28 (2008): 142-152.

Google Scholar, Crossref, Indexed at

3. Andrade, Raúl J., Guruprasad P. Aithal, Einar S. Björnsson and Neil Kaplowitz, et al. "EASL clinical practice guidelines: Drug-induced liver injury." J Hepatol 70 (2019): 1222-1261.

Google Scholar, Crossref, Indexed at

4. Jaeschke, Hartmut, Jephte Y. Akakpo, David S. Umbaugh and Anup Ramachandran. "Novel therapeutic approaches against acetaminophen-induced liver injury and acute liver failure." Toxicol Sci 174 (2020): 159-167.

Google Scholar, Crossref, Indexed at

5. Fisher, Erik S. and Steven C. Curry. "Evaluation and treatment of acetaminophen toxicity." Adv Pharm 85 (2019): 263-272.

Google Scholar, Crossref, Indexed at